Ten63 Therapeutics
Overview
Ten63 Therapeutics is a biotechnology firm headquartered in Durham, North Carolina, with a focus on computational drug discovery. The company targets the development of durable therapeutics for challenging diseases, particularly cancer, using advanced AI and physics-based models through its proprietary BEYOND platform. Ten63 aims to discover therapeutics that target previously undruggable targets, providing solutions to high unmet medical needs.
Leadership Team
- Marcel Frenkel, PhD: Co-founder and CEO, directs the strategic vision and operations of Ten63. Also serves on the board.
- Mark Hallen, PhD: Co-founder and CTO, specializes in the development of algorithms for drug discovery.
- Andrew Graham, CPA, MBA: CFO, provides strategic financial oversight with over 30 years of experience.
- Steve Sparks, PhD: VP and Head of Chemistry, an expert in medicinal chemistry and drug development.
- Charles Holst, PhD: VP and Head of Biology, experienced in drug discovery for oncology and inflammation.
- Nancy Miller-Rich: Co-Founder, involved in strategic direction and business partnerships.
- Bruce Donald: Founder and Chair, instrumental in technology development.
- Stephen Thomson: Head of Chemistry, involved in chemical research and development.
- Melissa Epstein: Head of IP Strategy, leads intellectual property management.
Financial Insights
Ten63 Therapeutics has successfully raised $21.3 million from investors including Alexandria Venture Investments and Hatteras Venture Partners, with a significant $15.9 million raised in an oversubscribed Series A round in May 2023. The company boasts a workforce of 16 employees and a robust annual growth rate of 60%.
Recent Developments
The company has announced a major multi-target drug discovery collaboration with Boehringer Ingelheim. This partnership leverages the BEYOND platform to explore novel drug candidates for Boehringer's portfolio, which includes targets with substantial unmet medical needs.
Technological Edge
The BEYOND platform enhances Ten63's prowess by facilitating the exploration of over 100 trillion synthetically feasible molecules. It integrates cryptic pocket discovery with generative AI-driven chemistry, allowing for the identification of potent drug candidates. The platform's predictive modeling for ADME (Absorption, Distribution, Metabolism, and Excretion) properties gives Ten63 a competitive advantage in drug discovery.
Strategic Vision
Ten63 Therapeutics aims to transform cancer treatment outcomes through its development of first-and-best-in-class therapeutics. The company's strategy involves fostering strategic partnerships, like that with Boehringer Ingelheim, to diversify and expand its pipeline across various health indications. The company continues to leverage its technological capabilities for broader global health impacts.
For more information, visit Ten63 Therapeutics at their official website: [Ten63 Therapeutics](https://www.ten63tx.com/).
Market Position and Competitor Analysis
Core Competitors
1. qPharmetra
- Revenue: $5.8 million
- Employees: 29
- Growth: 4%
2. NameBright
- Revenue: $3.2 million
- Employees: 16
- Growth: 0%
3. RTI Health Solutions
- Revenue: $83.2 million
- Employees: 414
- Growth: 7%
4. Lexitas Pharma Services
- Revenue: $31 million
- Employees: 154
- Growth: 56%
5. Clinical Ink
- Revenue: $66.6 million
- Employees: 265
6. BioDelivery Sciences International
- Revenue: $165.7 million
- Employees: 216
- Funding: $250.7 million
7. SOCIUM
- AI-powered drug discovery focusing on small molecules for unmet medical needs.
8. Auransa
- AI-native biopharma conducting data-driven cancer therapy discoveries.
9. Relay Therapeutics
- Specializes in precision medicine through insights into protein motion.
10. Molomics
- Uses AI and human intelligence to advance drug design.
Market Differentiators
Ten63 distinguishes itself in the competitive landscape with its proprietary in silico technology, enabling enduring therapeutic solutions. While many competitors focus on AI-driven repurposing or small-molecule discovery, Ten63's approach tackles drug resistance with innovative medicinal design.
Strategic Insights
Ten63 showcases a strong growth trajectory, a total workforce of 16 with a 60% annual growth rate, benefiting from strategic technology implementation. The company's recent financial achievements underscore its potential to leverage market trends for scaling operations and expanding its therapeutic pipeline, aligning with trends toward precision medicine.
For further insights and developments, access Ten63's detailed information on their [official website](https://www.ten63tx.com/).
